- Weight-Loss Drug Zepbound May Lower Heart Failure Deaths
- Nearly 160 Million Americans Harmed by Another’s Drinking, Drug Use
- 1 in 4 Americans Now Struggling to Cover Medical Costs
- Getting Fitter Can Really Help Keep Dementia at Bay
- Skin Patch Could Monitor Your Blood Pressure
- There May Be a Better Way to Treat Hematoma Brain Bleeds
- Chronic Joint Pain Plus Depression Can Take Toll on the Brain
- Living in Space Won’t Permanently Harm Astronauts’ Thinking Skills
- Kids’ Injuries in Sports and at Home: When Is It Right to Seek Medical Attention?
- Human Cell Atlas Will Be ‘Google Maps’ for Health Research
Brain Chemical Dopamine May Boost Risk-Taking in Healthy People
Higher levels of the brain chemical dopamine may increase risk-taking behaviors in healthy people, much like dopamine-boosting drugs have been shown to do in people with Parkinson’s disease, a small new study finds.
British researchers discovered that raising dopamine levels in healthy adults led to them taking greater risks when gambling.
Dopamine is a neurotransmitter associated with reward-based learning. Previous research has linked drugs that increase dopamine, such as L-DOPA, with compulsive gambling in Parkinson’s disease patients.
The new study included 30 people. They were asked to choose between safe and risky gambling options that resulted in monetary gains and losses. They did this after receiving L-DOPA and again after receiving an inactive placebo.
The participants took more risks to get bigger rewards after receiving L-DOPA, but not the placebo. However, L-DOPA did not affect how often the study volunteers took risks if there was a potential loss, the investigators found.
After receiving L-DOPA, the participants took more risks regardless of how much larger the potential reward was than the safer option, according to the study in the July 8 issue of the Journal of Neuroscience.
Participants were happier to win a small reward while on L-DOPA than on the placebo. They were happier to win a large reward than a small reward while on the placebo, but were equally happy about small rewards and large rewards while on L-DOPA, the findings showed.
L-DOPA made potential rewards more appealing but did not affect the participants’ perception of possible losses, according to study leader Robb Rutledge, of University College London in the United Kingdom, and his colleagues.
The study authors also suggested that while on L-DOPA, the participants might have had similar amounts of dopamine release for all gambling rewards, which may explain why they were equally happy after small and large wins.
These findings offer new insight into how dopamine levels affect decision-making and emotion, according to Nathaniel Daw, a neuroscientist at New York University in New York City, who was not involved in the study.
The study “may help to explain some kinds of gambling and impulse control problems, and also aspects of mood disorders,” he said in a Society for Neuroscience news release.
More information
Read more about risk-taking behaviors, such as gambling, in people being treated for Parkinson’s disease from the Parkinson’s Disease Foundation.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.